Rochem International Inc Rochem International Inc

X
[{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Kingswood Investments","pharmaFlowCategory":"D","amount":"$8.9 million","upfrontCash":"Undisclosed","newsHeadline":"MIRA Pharmaceuticals, Inc. Announces Pricing of $8.9 Million Initial Public Offering and Nasdaq Listing","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Kingswood Investments","pharmaFlowCategory":"D","amount":"$8.9 million","upfrontCash":"Undisclosed","newsHeadline":"MIRA Pharmaceuticals, Inc. Announces Closing of $8.9 Million Initial Public Offering","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"MZ Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MIRA Pharmaceuticals and MZ Group Partner to Strengthen Investor Relations and Shareholder Communication Efforts","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Mira Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Pharmaseed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MIRA Pharmaceuticals Announces Collaboration with Pharmaseed","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical"}]

Find Clinical Drug Pipeline Developments & Deals by Mira Pharmaceuticals

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The collaboration aims to assist MIRA in the research and development of Ketamir-2 (ketamir analog), which aids individuals struggling with major depressive disorder with suicidal ideation.

            Lead Product(s): Ketamine Analog

            Therapeutic Area: Psychiatry/Psychology Product Name: Ketamir-2

            Highest Development Status: Preclinical Product Type: Small molecule

            Recipient: Pharmaseed

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration February 08, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, MIRA will have the exclusive right in the U.S., Canada, and Mexico to develop and commercialize Ketamir-2, a novel oral ketamine analog designed to revolutionize the landscape of depressive disorder treatments.

            Lead Product(s): Ketamine Analog

            Therapeutic Area: Psychiatry/Psychology Product Name: Ketamir-2

            Highest Development Status: Preclinical Product Type: Small molecule

            Recipient: Miralogx

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement November 20, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The collaboration aims to enhance MIRA's visibility within the investment community and spotlight the potential of its drug candidate, MIRA1a (synthetic tetrahydrocannabinol analog), in treating anxiety, cognitive decline, and neuropathic pain.

            Lead Product(s): Synthetic Tetrahydrocannabinol Analog

            Therapeutic Area: Psychiatry/Psychology Product Name: MIRA1a

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: MZ Group

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration September 05, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The company expects to use the net proceeds to advance its clinical development programs, including MIRA1a (synthetic tetrahydrocannabinol analog), being developed as the first prescription drug to target the CB1 and CB2 receptors for chronic pain and anxiety.

            Lead Product(s): Tetrahydrocannabinol Analog,Cannabidiol

            Therapeutic Area: Psychiatry/Psychology Product Name: MIRA1A

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Kingswood Investments

            Deal Size: $8.9 million Upfront Cash: Undisclosed

            Deal Type: Public Offering August 07, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The company expects to use the net proceeds to advance its clinical development programs, including MIRA1a (synthetic tetrahydrocannabinol analog), being developed as the first prescription drug to target the CB1 and CB2 receptors for chronic pain and anxiety.

            Lead Product(s): Synthetic Tetrahydrocannabinol Analog

            Therapeutic Area: Psychiatry/Psychology Product Name: MIRA1a

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Kingswood Investments

            Deal Size: $8.9 million Upfront Cash: Undisclosed

            Deal Type: Public Offering August 02, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY